Riedel Richard F, Larrier Nicole, Dodd Leslie, Kirsch David, Martinez Salutario, Brigman Brian E
Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Curr Treat Options Oncol. 2009 Apr;10(1-2):94-106. doi: 10.1007/s11864-009-0088-2. Epub 2009 Feb 24.
Chondrosarcomas (CHS) represent a heterogeneous group of disorders ranging from indolent, low-grade tumors to aggressive, high-grade forms. Surgical resection represents the primary and preferred treatment modality for individuals with localized disease. Radiation therapy is appropriate for the treatment of positive surgical margins or palliation of disease-related symptoms. The treatment of advanced, metastatic disease is particularly challenging given the recognition that conventional chemotherapy has proven to be largely ineffective. Systemic chemotherapy may be considered in variant forms such as mesenchymal or dedifferentiated chondrosarcomas but high-quality data supporting its use is limited. There is universal agreement, however, that novel treatment strategies are desperately needed. This review will highlight the need for a coordinated multidisciplinary approach to optimize the management and care of patients.
软骨肉瘤（CHS）是一组异质性疾病，范围从惰性的低级别肿瘤到侵袭性的高级别肿瘤。手术切除是局限性疾病患者的主要且首选的治疗方式。放射治疗适用于手术切缘阳性或缓解疾病相关症状的治疗。鉴于传统化疗已被证明在很大程度上无效，晚期转移性疾病的治疗极具挑战性。对于间充质或去分化软骨肉瘤等变异型，可考虑全身化疗，但支持其使用的高质量数据有限。然而，大家普遍认为迫切需要新的治疗策略。本综述将强调需要一种协调的多学科方法来优化患者的管理和护理。
